Matches in SemOpenAlex for { <https://semopenalex.org/work/W2767436767> ?p ?o ?g. }
Showing items 1 to 91 of
91
with 100 items per page.
- W2767436767 endingPage "4074" @default.
- W2767436767 startingPage "4074" @default.
- W2767436767 abstract "4074 Background: Erdafitinib (JNJ-42756493) is a potent, oral pan-FGFR tyrosine kinase inhibitor that demonstrated encouraging preliminary clinical activity and manageable adverse events (AEs) in its first-in-human phase 1 study in advanced solid tumors (NCT01703481). Here we report results from pts with CCA from this study. Methods: This 4-part study enrolled pts age ≥ 18 years (y) with advanced solid tumors. Dose escalation (part 1) followed a 3+3 design, with pts receiving ascending doses of erdafitinib continuously or intermittently (7 days on/7 days off). Subsequent parts required FGFR gene alterations in the tumor, including activating mutations and translocations or other FGFR-activating aberrations. Part 2 was a pharmacodynamics cohort. Parts 3 and 4 were dose-expansion cohorts for recommended phase 2 doses of 9 mg once daily (QD) and 10 mg intermittently, respectively. Results: Eleven pts with FGFR-aberrant CCA were treated at 9 mg QD (n = 1) or 10 mg intermittent (n = 10). Median age was 60 y; 7 of 11 pts were female (64%). 73% of pts had ECOG performance status 1. All had prior systemic therapy. Median treatment duration with erdafitinib was 5.3 months (mo). Systemic erdafitinib exposure, per C max and AUC, in CCA pts was similar to other indications. The most common AEs were stomatitis (82%), hyperphosphatemia (64%), dry mouth (55%), dysgeusia (45%), dry skin (45%), and asthenia (45%), mostly grade 1/2 severity. No drug-related grade ≥3 AEs were reported in > 1 pt except grade 3 stomatitis (n = 2; 18%). The objective response rate, all confirmed partial responses (PRs) per RECIST 1.1, was 27.3% (3/11; 95% CI 6, 61); an additional 27.3% (3/11) had stable disease as their best response. Overall disease control rate was 55%. All 3 PRs were at the 10 mg intermittent dosage, and the median duration of response was 12.9 mo. With a median follow-up of 5.1 mo, median progression-free survival was 5.1 mo (95% CI 1.6, 16.4). As of the cutoff date, 2 pts continue on study treatment. Conclusions: Erdafitinib showed encouraging clinical activity and minimal toxicity in pts with advanced CCA and FGFR alterations. These results warrant further study. Clinical trial information: NCT01703481." @default.
- W2767436767 created "2017-11-17" @default.
- W2767436767 creator A5000978310 @default.
- W2767436767 creator A5005968330 @default.
- W2767436767 creator A5006620245 @default.
- W2767436767 creator A5015509025 @default.
- W2767436767 creator A5021624793 @default.
- W2767436767 creator A5024388671 @default.
- W2767436767 creator A5045670207 @default.
- W2767436767 creator A5048842913 @default.
- W2767436767 creator A5052658465 @default.
- W2767436767 creator A5055055894 @default.
- W2767436767 creator A5068824818 @default.
- W2767436767 creator A5075296860 @default.
- W2767436767 creator A5078885964 @default.
- W2767436767 creator A5081735541 @default.
- W2767436767 creator A5083417260 @default.
- W2767436767 creator A5088868208 @default.
- W2767436767 date "2017-05-20" @default.
- W2767436767 modified "2023-10-01" @default.
- W2767436767 title "Safety and activity of the pan-fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients (Pts) with molecularly selected advanced cholangiocarcinoma (CCA)." @default.
- W2767436767 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.4074" @default.
- W2767436767 hasPublicationYear "2017" @default.
- W2767436767 type Work @default.
- W2767436767 sameAs 2767436767 @default.
- W2767436767 citedByCount "18" @default.
- W2767436767 countsByYear W27674367672017 @default.
- W2767436767 countsByYear W27674367672018 @default.
- W2767436767 countsByYear W27674367672019 @default.
- W2767436767 countsByYear W27674367672020 @default.
- W2767436767 countsByYear W27674367672021 @default.
- W2767436767 countsByYear W27674367672022 @default.
- W2767436767 countsByYear W27674367672023 @default.
- W2767436767 crossrefType "journal-article" @default.
- W2767436767 hasAuthorship W2767436767A5000978310 @default.
- W2767436767 hasAuthorship W2767436767A5005968330 @default.
- W2767436767 hasAuthorship W2767436767A5006620245 @default.
- W2767436767 hasAuthorship W2767436767A5015509025 @default.
- W2767436767 hasAuthorship W2767436767A5021624793 @default.
- W2767436767 hasAuthorship W2767436767A5024388671 @default.
- W2767436767 hasAuthorship W2767436767A5045670207 @default.
- W2767436767 hasAuthorship W2767436767A5048842913 @default.
- W2767436767 hasAuthorship W2767436767A5052658465 @default.
- W2767436767 hasAuthorship W2767436767A5055055894 @default.
- W2767436767 hasAuthorship W2767436767A5068824818 @default.
- W2767436767 hasAuthorship W2767436767A5075296860 @default.
- W2767436767 hasAuthorship W2767436767A5078885964 @default.
- W2767436767 hasAuthorship W2767436767A5081735541 @default.
- W2767436767 hasAuthorship W2767436767A5083417260 @default.
- W2767436767 hasAuthorship W2767436767A5088868208 @default.
- W2767436767 hasConcept C126322002 @default.
- W2767436767 hasConcept C141071460 @default.
- W2767436767 hasConcept C170493617 @default.
- W2767436767 hasConcept C197934379 @default.
- W2767436767 hasConcept C2777054765 @default.
- W2767436767 hasConcept C2778375690 @default.
- W2767436767 hasConcept C71924100 @default.
- W2767436767 hasConcept C74373430 @default.
- W2767436767 hasConcept C82867764 @default.
- W2767436767 hasConcept C90924648 @default.
- W2767436767 hasConceptScore W2767436767C126322002 @default.
- W2767436767 hasConceptScore W2767436767C141071460 @default.
- W2767436767 hasConceptScore W2767436767C170493617 @default.
- W2767436767 hasConceptScore W2767436767C197934379 @default.
- W2767436767 hasConceptScore W2767436767C2777054765 @default.
- W2767436767 hasConceptScore W2767436767C2778375690 @default.
- W2767436767 hasConceptScore W2767436767C71924100 @default.
- W2767436767 hasConceptScore W2767436767C74373430 @default.
- W2767436767 hasConceptScore W2767436767C82867764 @default.
- W2767436767 hasConceptScore W2767436767C90924648 @default.
- W2767436767 hasIssue "15_suppl" @default.
- W2767436767 hasLocation W27674367671 @default.
- W2767436767 hasOpenAccess W2767436767 @default.
- W2767436767 hasPrimaryLocation W27674367671 @default.
- W2767436767 hasRelatedWork W2003938723 @default.
- W2767436767 hasRelatedWork W2047967234 @default.
- W2767436767 hasRelatedWork W2087016115 @default.
- W2767436767 hasRelatedWork W2118496982 @default.
- W2767436767 hasRelatedWork W2349164817 @default.
- W2767436767 hasRelatedWork W2364998975 @default.
- W2767436767 hasRelatedWork W2439875401 @default.
- W2767436767 hasRelatedWork W2885761574 @default.
- W2767436767 hasRelatedWork W4238867864 @default.
- W2767436767 hasRelatedWork W2525756941 @default.
- W2767436767 hasVolume "35" @default.
- W2767436767 isParatext "false" @default.
- W2767436767 isRetracted "false" @default.
- W2767436767 magId "2767436767" @default.
- W2767436767 workType "article" @default.